Aby J. Mathew - 06 Oct 2026 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Reporting relationship: EVP & Chief Scientific Officer
Issuer ticker: BLFS
Reported as of: 06 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Oct 2026, 21:57:42 UTC
Prior SEC filing: 22 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Aby J. Mathew

Key filing fact

Aby J. Mathew filed Form 4 for BIOLIFE SOLUTIONS INC (BLFS) on 08 Oct 2026.

Key facts

This page summarizes Aby J. Mathew's Form 4 filing for BIOLIFE SOLUTIONS INC (BLFS).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 08 Oct 2026, 21:57.

Change

Previous filing in this sequence was filed on 22 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001556355 Primary reporting owner

Mathew Aby J.

Relationship: EVP & Chief Scientific Officer
Address: 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL
Signature: /s/ Aby J. Mathew
Signature date: 08 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BLFS transaction

Common Stock

Award

Transaction value
Shares: +45,838
Change %: +15%
Price
Shares after: 343,866
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F2

BLFS transaction

Common Stock

Award

Transaction value
Shares: +40,192
Change %: +12%
Price
Shares after: 384,058
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F3

BLFS transaction

Common Stock

Tax liability

Transaction value
Shares: -70,000
Change %: -18%
Price: $38.61^*
Shares after: 314,058
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F4

BLFS transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -404,608
Change %: -100%
Price
Shares after: 0
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Aby J. Mathew is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 4 footnotes

Footnote F1

Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.

Footnote F2

The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan"). In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2025 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Footnote F3

The restricted stock was granted pursuant to the 2023 Plan. In accordance with the terms of the grant and the Merger Agreement, the restricted stock vested immediately prior to the First Merger Effective Time as to approximately 200% of the number of shares granted based on the Registrant's total shareholder return during the period beginning on January 1, 2026 through October 2, 2026 as compared to the total shareholder return of certain of the Registrant's peers (such peers have been determined by the Registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Footnote F4

Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.